Therapeutic VHH proteins

Therapeutic VHH proteins are single-domain antibody fragments derived from heavy-chain-only antibodies found in camelids. Their small size (~15 kDa), high solubility, and exceptional stability under a wide range of conditions make them powerful tools in therapeutic development. Unlike conventional monoclonal antibodies, nanobodies can access hidden or sterically restricted epitopes, allowing them to neutralize targets with higher precision.

VHH proteins exhibit high affinity and specificity for their targets, ranging from extracellular receptors to intracellular proteins. Their mechanisms include:

• Blocking ligand-receptor interactions
• Neutralizing toxins and viral particles
• Modulating enzyme activity
• Acting as carriers for drug delivery or diagnostics

Due to their robustness, VHH molecules are ideal for inhalable formulations, topical applications, and even intracellular delivery.

Therapeutic VHH proteins are transforming life science research and clinical development:

• Oncology: Blocking immune checkpoints (e.g., PD-L1) and targeting tumor-specific antigens
• Infectious diseases: Neutralizing viral proteins, including SARS-CoV-2 spike protein
• Neurodegenerative diseases: Crossing the blood-brain barrier for targeted delivery
• Diagnostics: Imaging agents due to rapid clearance and high tissue penetration

Choosing the right VHH depends on your project needs. Here are some considerations:

• Define the target (e.g., membrane protein, toxin, intracellular protein)
• Determine the required affinity and epitope specificity
• Consider the final format: naked nanobody, Fc-fusion, or drug conjugate
• Assess delivery route and formulation constraints (e.g., systemic vs. local)
• Validate stability, aggregation profile, and manufacturability

ProteoGenix offers biosimilar VHH proteins tailored for therapeutic, diagnostic, and research applications. Our expertise ensures seamless integration into your therapeutic development pipeline.